XenoPort, GlaxoSmithKline sales and marketing update

GlaxoSmithKline said it has experienced "spot outages" of Horizant gabapentin enacarbil, which is approved to treat restless legs syndrome (RLS) and to manage postherpetic neuralgia (PHN), due to undisclosed manufacturing delays. GSK said certain patients may not be able to have prescriptions filled in the near term and that it is working to resolve the issue. Partner XenoPort, which could not be reached for details, said it expects Horizant to be available in pharmacies in June.

Last November, GSK and XenoPort mutually agreed to terminate an amended 2007 deal under which the pharma has U.S. commercialization rights to Horizant. The termination settled a lawsuit between the partners to determine whether GSK fulfilled its contractual obligations to maximize sales of Horizant (see BioCentury, Nov. 12, 2012). ...